$CLLS

Cellectis S.A.

CIK:0001627281|SEC Filings

Statements of Consolidated Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Profit or loss [abstract]
Revenues	$ 72,949	$ 41,505	$ 755
Other income	6,644	7,712	8,438
Total revenues and other income	79,592	49,217	9,193
Operating expenses
Cost of revenue	0	0	(737)
Research and development expenses	(93,517)	(90,536)	(87,646)
Selling, general and administrative expenses	(19,790)	(19,085)	(16,812)
Other operating income (expenses)	638	849	(1,300)
Total operating expenses and other operating income	(112,669)	(108,771)	(106,495)
Operating income (loss)	(33,076)	(59,554)	(97,302)
Financial income	16,124	44,407	21,479
Financial expenses	(51,064)	(21,614)	(40,642)
Net Financial gain (loss)	(34,940)	22,793	(19,163)
Tax income (expense)	423	0	(371)
Income (loss) from continuing operations	(67,593)	(36,761)	(116,835)
Income (loss) from discontinued operations	0	0	8,392
Net income (loss)	(67,593)	(36,761)	(108,443)
Attributable to shareholders of Cellectis	(67,593)	(36,761)	(101,059)
Attributable to non-controlling interests	$ 0	$ 0	$ (7,384)
Basic / Diluted net income (loss) per share attributable to shareholders of Cellectis
Basic net income (loss) attributable to shareholders of Cellectis, per share ($ /share)	$ (0.67)	$ (0.41)	$ (1.77)
Diluted net income (loss) attributable to shareholders of Cellectis, per share ($ /share)	(0.67)	(0.41)	(1.77)
Basic net income (loss) attributable to shareholders of Cellectis from discontinued operations, per share ($ /share)	0	0	0.28
Diluted net income (loss) attributable to shareholders of Cellectis from discontinued operations, per share ($ /share)	$ 0	$ 0	$ 0.28
Number of shares used for computing
Basic	100,279,276	90,566,346	57,012,815
Diluted	100,279,276	90,566,346	57,012,815

Statements of Consolidated Cash Flows - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2025

Dec. 31, 2024

Dec. 31, 2023

Cash flows from operating activities

Net income (loss)

$ (67,593)

$ (36,761)

$ (108,443)

Net loss for the period from discontinued operations

8,392

Net (loss) income for the period from continuing operations

(67,593)

(36,761)

(116,835)

Adjustment to reconcile net income (loss) to cash provided by (used in) operating activities

Amortization and depreciation

20,062

19,846

18,523

Net loss (income) on disposals

Net financial loss (gain)

34,940

(22,793)

19,163

Income tax

(423)

(539)

371

6,110

3,167

5,233

Provisions

334

(1,875)

1,352

Other non-cash items

2,010

(1,402)

Realized foreign exchange gain (loss)

339

(308)

Operating cash flows before change in working capital

(6,231)

(37,233)

(73,588)

Decrease (increase) in trade receivables and other current assets

^[1]

(5,020)

52,596

2,252

Decrease (increase) in subsidies and tax receivables

(4,431)

(6,734)

(6,238)

(Decrease) increase in trade payables and other current liabilities

(3,259)

2,055

(6,305)

(Decrease) increase in deferred revenues and contract liabilities

(28,883)

5,748

59,149

Change in working capital

(41,593)

53,665

48,859

Interest received

8,428

6,558

3,627

Income tax received (paid)

(5)

Net cash flows provided by (used in) operating activities of continuing operations

(39,401)

22,989

(21,103)

Net cash flows provided by (used in) operating activities of discontinued operations

(3,644)

Net cash flows provided by (used in) operating activities

(39,401)

22,989

(24,746)

Cash flows from investment activities

Acquisition of intangible assets

(1,173)

(1,260)

Calyxt's cash and cash equivalents disposed of

(1,642)

Acquisition of property, plant and equipment

(2,360)

(2,583)

(1,073)

Sales of non-current financial assets

158

489

Sale of current financial assets

133,669

63,806

Acquisition of non-current financial assets

(2)

Acquisition of current financial assets

(159,777)

(162,768)

(13,363)

Net cash flows provided by (used in) investing activities of continuing operations

(29,484)

(102,808)

(15,589)

Net cash flows provided by (used in) investing activities of discontinued operations

Cash flows provided by (used in) investment activities

(29,484)

(102,808)

(15,510)

Cash flows from financing activities

Proceeds from issue of share capital and other equity instruments after deduction of transaction costs

82,822

67,936

Increase in borrowings

23,201

29,671

Decrease in borrowings

(5,379)

(5,001)

(5,107)

Interest paid on financial debt

(612)

(847)

(333)

Payments on lease debts

(10,814)

(11,062)

(11,084)

Net cash flows provided by (used in) financing activities of continuing operations

(16,761)

89,113

81,084

Net cash flows provided by (used in) financing activities of discontinued operations

1,781

Net cash flows provided by (used in) financing activities

(16,761)

89,113

82,865

(Decrease) increase in cash and cash equivalents

(85,647)

9,295

42,608

Cash and cash equivalents at the beginning of the year

143,251

136,708

93,216

Effect of exchange rate changes on cash

3,928

(2,752)

884

Cash from discontinued operations

Cash from continuing operations

61,533

143,251

136,708

Cash and cash equivalents at the end of the period

$ 61,533

$ 143,251

$ 136,708

[1]

For the year ended December 31, 2024, the $140.0 million cash received from AstraZeneca related to Cellectis' capital increase is recorded as cash-flows from operating activities for $57.0 million related to the SIA derivative and as cash-flows from financing activities for $82.8 million (after deduction of transactions costs amounting to $0.2 million)– see note 2.6.

Statements of Consolidated Financial Position - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Non-current assets
Intangible assets	$ 535	$ 1,116
Property, plant and equipment	38,788	45,895
Right-of-use assets	23,658	29,968
Non-current financial assets	5,088	7,521
Other non-current assets	20,025	11,594
Deferred tax assets	382	382
Total non-current assets	88,476	96,476
Current assets
Trade receivables	14,398	6,714
Subsidies receivables	7,800	14,521
Other current assets	5,383	5,528
Current financial assets	147,130	117,055
Cash and cash equivalents	61,533	143,251
Total current assets	236,244	287,069
TOTAL ASSETS	324,720	383,544
Shareholders' equity
Share capital	5,903	5,889
Premiums related to the share capital	437,445	494,288
Currency translation adjustment	(33,316)	(39,537)
Retained earnings (deficit)	(266,538)	(292,846)
Net income (loss)	(67,593)	(36,761)
Total shareholders' equity - Group Share	75,901	131,033
Total shareholders' equity	75,901	131,033
Non-current liabilities
Non-current financial liabilities	74,013	50,882
Non-current lease debts	27,725	34,245
Non-current provisions	1,329	1,115
Total non-current liabilities	103,067	86,241
Current liabilities
Current financial liabilities	10,460	16,134
Current lease debts	7,701	8,385
Trade payables	17,277	18,664
Deferred income and contract liabilities	96,803	112,161
Current provisions	1,169	828
Other current liabilities	12,342	10,097
Total current liabilities	145,752	166,269
Total liabilities	248,819	252,511
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 324,720	$ 383,544